Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Other Accumulated Expenses (2018 - 2025)

Historic Other Accumulated Expenses for Bio (TELA) over the last 8 years, with Q3 2025 value amounting to $1.2 million.

  • Bio's Other Accumulated Expenses rose 4232.67% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 4232.67%. This contributed to the annual value of $955000.0 for FY2024, which is 8121.44% up from last year.
  • As of Q3 2025, Bio's Other Accumulated Expenses stood at $1.2 million, which was up 4232.67% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Bio's Other Accumulated Expenses registered a high of $1.2 million during Q2 2025, and its lowest value of $51000.0 during Q1 2022.
  • For the 5-year period, Bio's Other Accumulated Expenses averaged around $488210.5, with its median value being $278000.0 (2023).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first crashed by 9172.08% in 2022, then surged by 28589.74% in 2024.
  • Bio's Other Accumulated Expenses (Quarter) stood at $79000.0 in 2021, then soared by 84.81% to $146000.0 in 2022, then soared by 260.96% to $527000.0 in 2023, then surged by 81.21% to $955000.0 in 2024, then rose by 20.42% to $1.2 million in 2025.
  • Its Other Accumulated Expenses was $1.2 million in Q3 2025, compared to $1.2 million in Q2 2025 and $1.1 million in Q1 2025.